Literature DB >> 11571239

Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption.

U E Heidland1, B E Strauer.   

Abstract

BACKGROUND: Plaque disruption is the central pathophysiological mechanism underlying acute coronary syndromes and the progression of coronary atherosclerosis. There exists only scant information about the factors that are associated with its development. The aim of the current study was to analyze the contribution of hemodynamic forces in the pathogenesis of plaque disruption. Plaque disruption was diagnosed by coronary angiography of stenosed but not completely occluded coronary arteries. METHODS AND
RESULTS: This study retrospectively analyzed 106 patients who underwent 2 coronary angiography procedures within 6 months. We investigated 53 patients with initially smooth stenoses who developed plaque disruption by the time of the second coronary angiogram and compared these patients with 53 age- and sex-matched individuals with smooth stenoses without angiographic signs of plaque disruption. The 2 groups were compared by analyzing central hemodynamics, echocardiographic measurements, and cardiovascular medication use. Logistic regression analysis identified positive associations between plaque disruption, left ventricular muscle mass >270 g, and a mean heart rate >80 bpm and a negative association with the use of beta-blockers.
CONCLUSIONS: The associations documented by our investigation indicate that hemodynamic forces may play a crucial role in the pathogenesis of plaque disruption. These findings may help to identify patients who are at an increased risk of plaque disruption and who might gain benefit from pharmacological interventions aimed at reducing heart rate, for example, by the use of beta-blockers, or a reduction of left ventricular hypertrophy.

Entities:  

Mesh:

Year:  2001        PMID: 11571239     DOI: 10.1161/hc3801.096325

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  70 in total

1.  Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.

Authors:  Sebastian Nuding; Henning Ebelt; Robert S Hoke; Annette Krummenerl; Andreas Wienke; Ursula Müller-Werdan; Karl Werdan
Journal:  Clin Res Cardiol       Date:  2011-06-03       Impact factor: 5.460

Review 2.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

Review 3.  Role of heart rate as a marker and mediator of poor outcome for patients with heart failure.

Authors:  John R Kapoor; Paul A Heidenreich
Journal:  Curr Heart Fail Rep       Date:  2012-06

4.  Prognostic significance of heart rate in hospitalized patients presenting with myocardial infarction.

Authors:  Lorenzo Fácila; Pedro Morillas; Juan Quiles; Federico Soria; Alberto Cordero; Pilar Mazón; Manuel Anguita; Cándido Martín-Luengo; Jose Ramón Gonzalez-Juanatey; Vicente Bertomeu
Journal:  World J Cardiol       Date:  2012-01-26

5.  Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus.

Authors:  G S Hillis; M Woodward; A Rodgers; C K Chow; Q Li; S Zoungas; A Patel; R Webster; G D Batty; T Ninomiya; G Mancia; N R Poulter; J Chalmers
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

Review 6.  Circadian rhythm and cardiovascular disease.

Authors:  Elizabeth Shaw; Geoffrey H Tofler
Journal:  Curr Atheroscler Rep       Date:  2009-07       Impact factor: 5.113

Review 7.  Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms.

Authors:  Paolo Palatini
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Clinical results of I(f) current inhibition by ivabradine.

Authors:  Jean-Claude Tardif
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  [Heart rate reduction as a therapeutic strategy: novel options].

Authors:  U C Hoppe
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

10.  Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.

Authors:  Fabio Mangiacapra; Iginio Colaiori; Elisabetta Ricottini; Francesco Balducci; Antonio Creta; Chiara Demartini; Giorgio Minotti; Germano Di Sciascio
Journal:  Clin Res Cardiol       Date:  2016-08-12       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.